These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

570 related items for PubMed ID: 31759966

  • 1. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S, Dell'Aniello S, Ernst P.
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [Abstract] [Full Text] [Related]

  • 3. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2019 Jun; 155(6):1158-1165. PubMed ID: 30922950
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 5. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y, Keeney E, Ghatehorde N, Dias S.
    Cochrane Database Syst Rev; 2018 Dec 03; 12(12):CD012620. PubMed ID: 30521694
    [Abstract] [Full Text] [Related]

  • 6. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH, Tan DJ, Walters JA, Walters EH.
    Cochrane Database Syst Rev; 2023 Dec 06; 12(12):CD011600. PubMed ID: 38054551
    [Abstract] [Full Text] [Related]

  • 7. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 06; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 8. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.
    Cochrane Database Syst Rev; 2017 Feb 10; 2(2):CD012066. PubMed ID: 28185242
    [Abstract] [Full Text] [Related]

  • 9. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
    Suissa S, Dell'Aniello S, Ernst P.
    COPD; 2022 Dec 10; 19(1):1-9. PubMed ID: 34544314
    [Abstract] [Full Text] [Related]

  • 10. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 10; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

  • 11. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 10; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 12. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct 10; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

  • 13. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM, Thomas EC.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 10; 12():1877-1882. PubMed ID: 28694698
    [Abstract] [Full Text] [Related]

  • 14. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
    Suissa S, Dell'Aniello S, Ernst P.
    COPD; 2021 Feb 10; 18(1):1-8. PubMed ID: 33569990
    [Abstract] [Full Text] [Related]

  • 15. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E.
    Respir Med; 2018 Sep 10; 142():73-80. PubMed ID: 30170806
    [Abstract] [Full Text] [Related]

  • 16. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 10; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 17. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
    Feldman WB, Avorn J, Kesselheim AS, Gagne JJ.
    JAMA Intern Med; 2023 Jul 01; 183(7):685-695. PubMed ID: 37213116
    [Abstract] [Full Text] [Related]

  • 18. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
    Meeraus W, Wood R, Jakubanis R, Holbrook T, Bizouard G, Despres J, Silva CCD, Nachbaur G, Landis SH, Punekar Y, Aguilaniu B, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 01; 14():51-63. PubMed ID: 30587961
    [Abstract] [Full Text] [Related]

  • 19. Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD.
    Lee EG, Kim Y, Hwang YI, Yoo KH, Lee SE, Jung KY, Lee D, Park YB, Rhee CK.
    Sci Rep; 2023 May 20; 13(1):8183. PubMed ID: 37210420
    [Abstract] [Full Text] [Related]

  • 20. Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study.
    Bloom CI, Douglas I, Usmani OS, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2020 May 20; 15():701-710. PubMed ID: 32308379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.